TO THE EDITOR Erythrocytosis is the critical feature separating polycythemia vera (PV) from the other chronic myeloproliferative diseases. Although a number of growth factors including erythropoietin, stem cell factor, and c-kit are involved in cell signaling, proliferation, and differentiation, the fundamental basis for autonomous erythropoiesis in PV remains unknown. Plateletderived growth factor is involved in the development of marrow fibrosis during the course of PV. Since imatinib mesylate (IM) inhibits c-kit and PDGF-R (and of course BCR-ABL), its effect in PV is of considerable interest.
We studied seven patients with PV to determine whether phlebotomy requirements could be reduced with normalization of the hematocrit, to p45% in men and p42% in women, and the platelet count reduced to ml p600 000/ml. We also noted the effect of imatinib on splenomegaly (if present) and on side effects and the general quality of life of the patients.
An increased red cell mass was defined as an increase 425% above the normal predicted value, except for men with a hct of 460% or women with a hct 456%.
131 I plasma volume was also determined. Then, any three of the six criteria shown in Table 1 were required. In all cases, bone marrow aspiration smears stained for iron disclosed absent iron stores and cytogenetic studies did not reveal the Philadelphia chromosome. Patients were either newly diagnosed, interferon refractory, resistant or intolerant or were not controlled by hydroxyurea.
Treatment was started at a dose of 400 mg daily. Dose escalation was permitted to a maximum of 800 mg daily for persistent phlebotomy requirements, thrombocytosis, or splenomegaly.
The demographics of the seven patients studied to date are shown in Table 2 . The three men and four women were relatively young, stressing the importance in carefully selecting therapy for individuals under the age of 50 years. Prior treatments in addition to phlebotomy are shown in Table 2 .
Treatment duration has only lasted approximately 6 months to date. Nevertheless, if we examine the change of phlebotomy requirements for 3 month periods before and during imatinib therapy, there is change in six of seven patients (Figure 1) . Since not all patients were seen by us initially, and since they may not have been phlebotomized with the same vigor with which we do, these differences may even have been greater.
In Table 3 is shown the months on trial, and the phlebotomy requirements at baseline and during treatment. Months phlebotomy free are shown in the last column. The second patient had grade 3 dermatitis was removed from study 1.6 months after beginning IM and has since required two phlebotomies. All patients had an elevated platelet count before or during IM and four have returned to below 600 000/ml while three remain elevated. Table 1 PV diagnostic criteria K Red cell mass >25% above normal predicted value 3 Exception: men with hct >60% or women with hct >56%
K Exclude secondary erythrocytosis K Any three of the following: 3 Clinically palpable spleen 3 Bone marrow consistent with PV 3 Clonality markers (cytogenetic abnormalities) 3 Platelet count >600 000/ml 3 WBC >12 000/ml 3 Serum epo level o25 mU/ml Figure 1 Phlebotomy requirements per quarter (3 months).
Change in spleen size occurred in two patients who had an enlarged spleen prior to imatinib. In one, it reduced in size by 75%, and in the second, a patient with a much smaller spleen, it became nonpalable.
Six of seven patients required an increase in imatinib dose because of persistent thrombocytosis, splenomegaly, or phlebotomy requirements to date. In five, the dose was more than 500 mg daily. Imatinib mesylate was remarkably well tolerated except for one patient who developed grade 3 dermatitis for whom it had to be discontinued.
I conclude that imatinib mesylate is effective in PV in reducing phlebotomy requirements, in lowering abnormal platelet counts, and reducing spleen size. Continued investigation is warranted to determine long-term response, optimum dose, duration, and side effects. 
